AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the theft of trade secrets. Genmab has vowed to “vigorously defend ...

AbbVie (ABBV) closed the most recent trading day at $209.17, moving -0.4% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.77%. At the same time ...

April 3 (Reuters) - AbbVie (ABBV.N), opens new tab on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone ...

Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

So, you want to invest in AbbVie (ABBV 2.33%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?

AbbVie (NYSE:ABBV) shares snap seven straight sessions of losses, as the stock ended 0.71% higher at $202.72 on Thursday. The biopharmaceutical company lost nearly 6% in the preceding seven ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and valleys. Even if there’s a city off in the distance to your right, it does ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

Ross, M.D., Ph.D., vice president, early oncology research and development, AbbVie. "By harnessing the latest scientific breakthroughs in translational research, we are advancing novel therapeutic ...

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and ...